Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene’s confidence in IO/IO combinations.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 2 September 2022, including: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene, Ltd.’s confidence in IO/IO combinations.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data" - Scrip, 29 Aug, 2022.)
(Also see "Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure" - Scrip, 29 Aug, 2022.)
(Also see "Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial" - Scrip, 30 Aug, 2022.)
(Also see "MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent" - Scrip, 29 Aug, 2022.)
(Also see "BeiGene Is Keeping The Faith In IO/IO Combinations" - Scrip, 31 Aug, 2022.)